PANKU-Breast01 🇨🇳: dual EGFR and HER3 ADC Iza-Bren vs TPC in HR+/HER2- pre-treated MBC:

Back to meeting Original

Back to meeting

Philippe Aftimos, MD · @aftimosp · X·2026-10-23 21:02· 2 days agoScore70

PANKU-BREAST01

Body

PANKU-Breast01 🇨🇳: dual EGFR and HER3 ADC Iza-Bren vs TPC in HR+/HER2- pre-treated MBC:

🔹 Median PFS improvement with Iza-bren: 8.2 vs 4 months (HR 0.41)
🔹 OS immature
🔸 More grade 3 AEs with Iza-bren

#ESMO26 #ESMOAmbassadors
@myESMO @PTarantinoMD @E_de_Azambuja

373 views · 3 likes · 2 reposts · 0 replies

Conference abstracts

LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage

PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

https://esmocongress.esmo.org

Source: Philippe Aftimos, MD  · x.com